SCHEDULE 13G: Millennium Management Entities Reduce Stake in Caris Life Sciences Below 5%

Millennium Management LLC and affiliated entities have filed a Schedule 13G, disclosing a beneficial ownership of 1.3% in Caris Life Sciences, Inc., after previously exceeding the 5% threshold.

Summary

• Riverview Group LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander filed a Schedule 13G regarding their beneficial ownership of Caris Life Sciences, Inc. Common Stock.
• Riverview Group LLC beneficially owns 2,985,503 shares, representing 1.1% of the class, with shared voting and dispositive power over all these shares.
• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each beneficially own 3,583,100 shares, representing 1.3% of the class, with shared voting and dispositive power over all these shares.
• The reporting persons initially acquired beneficial ownership of more than 5% of the outstanding Common Stock on June 17, 2025, which triggered the filing requirement.
• By the filing date of June 23, 2025, the reporting persons had ceased to be beneficial owners of more than 5% of the outstanding Common Stock.
• The securities are not held for the purpose of changing or influencing control of Caris Life Sciences, Inc.

Sentiment

Score: 4

Explanation: The document reports a reduction in beneficial ownership from over 5% to lower percentages by significant institutional investors, which could be interpreted negatively by the market, although the filing itself is a standard disclosure.

Negatives

• The reporting persons, including Millennium Management LLC and affiliates, reduced their beneficial ownership in Caris Life Sciences, Inc. from over 5% to 1.1% (Riverview Group LLC) and 1.3% (Millennium entities) by the filing date. This reduction from a significant stake could be perceived negatively by the market.

Risks

• Potential negative market perception due to a significant institutional investor reducing its stake from over 5% to a lower percentage.

Future Outlook

NA

Management Comments

• After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

NA

Stakeholder Impact

• Shareholders: May react to the reduction in stake by a prominent institutional investor, potentially leading to negative sentiment or share price pressure.

Key Dates

Keywords

Caris Life Sciences, Millennium Management LLC, Riverview Group LLC, Israel A. Englander, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Equity Stake